Market Overview

Top 4 NASDAQ Stocks In The Drugs-Generic Industry With The Highest Revenue

Share:
Related MYL
Mylan Confirms USPTO Institutes Inter Partes Review Proceedings vs Two Copaxone 40 mg/mL Dosing Patents
The Coming Drug-Patent Cliff Is Pushing This Portfolio Up
Mylan (Investor's Business Daily)
Related SLXP
Benzinga's Volume Movers
US Stock Futures Edge Lower Ahead Of ADP Report

Below are the top drugs-generic stocks on the NASDAQ in terms of revenue.

The trailing-twelve-month revenue at Mylan (NASDAQ: MYL) is $6.39 billion. Mylan's ROA for the same period is 5.89%.

The trailing-twelve-month revenue at Salix Pharmaceuticals Ltd (NASDAQ: SLXP) is $605.72 million. Salix Pharmaceuticals had $665.87 million in total cash for the latest quarter.

The trailing-twelve-month revenue at Hi Tech Pharmacal Co (NASDAQ: HITK) is $230.00 million. Hi Tech Pharmacal's ROE for the same period is 23.17%.

The trailing-twelve-month revenue at Akorn (NASDAQ: AKRX) is $163.19 million. Akorn's operating margin for the same period is 26.68%.

Posted-In: Drugs-Generic Industry Highest Revenue NASDAQTrading Ideas

 

Related Articles (AKRX + HITK)

Get Benzinga's Newsletters